Association between Treatment Response and Potential Indicators of Efficacy and Safety in a Phase III Trial of Decitabine in Older Patients with Acute Myeloid Leukemia

Mark D. Minden^1*, Christopher Arthur², Jiří Mayer³, Mark M. Jones⁴, Erhan Berrak⁴ and Hagop Kantarjian⁵

¹Ontario Cancer Institute/Princess Margaret Hospital, Division of Stem Cell and Developmental Biology, Toronto, Ontario, Canada

²Royal North Shore Hospital, Department of Haematology, St. Leonards, Australia

³Masaryk University Hospital Brno, and CEITEC, Masaryk University, Czech Republic

⁴Eisai Inc., Oncology Product Creation Unit, Woodcliff Lake, NJ, USA

⁵The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX, USA